INSIGHTS
What’s Happening in AAV Gene Therapy Now
-
insightsScience in Action: Shared Time, Shared Purpose At Viralgen, our work is driven by a clear mission: applying science to improve people’s lives. Last December, that mission extended beyond our...Read More about Science in Action: Shared Time, Shared PurposeDecember 17, 2025 -
insightsOur scientific and business teams at Viralgen have been crisscrossing the globe to get insights on our peers’ latest advances in cell and gene therapy – and to share our own. Here’s a quick rundown... -
insightsAuthors: María Iglesias, Head of Digital & IT Jens Keune, Data Science & Digital Product Manager
-
insights“Understand that we are the only ones capable of doing this task, because we’ve cared from the very beginning, because we have the capabilities, and because we can bring all the pieces together. So... -
insightsThe article, written by María Iglesias, Digital & IT Head at Viralgen, explores how digitalization has transformed the manufacturing processes of adeno-associated viral (AAV) vectors at the company....Read More about Digital Transformation at ViralgenJanuary 29, 2025 -
insightsLast week we had the opportunity to host Sonia Guirado, a member of the Eurofirms Foundation and a renowned Paralympic medalist of the Barcelona '92 and Atlanta '96 Games. During her talk, Sonia...
-
insightsViralgen Vector Core, S.L. ha obtenido una vez más apoyo desde el Gobierno Vasco a través del Programa Bilakatu de Ayuda a empresas afectadas por el Covid-19 – Convocatoria 2022. Esta iniciativa está... -
insightsViralgen Vector Core, S.L. ha obtenido una vez más apoyo desde el Gobierno Vasco a través del Programa Bilakatu de Ayuda a empresas afectadas por el Covid-19 – Convocatoria 2022. Esta iniciativa está...
-
insightsVIRALGEN VECTOR CORE, S.L. has secured vital support from the HAZITEK Business R&D Support Program of the Basque Government-Call 2023. This collaborative initiative, backed by the European Regional...
-
insightsViralgen Vector Core and Elpida Therapeutics partner to manufacture gene therapy medicines for anticipated Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) clinical trials
-
insightsLast week, we participated in the ASGCT 26th Annual Meeting, which was held in Los Angeles.Read More about Successful meeting at the ASGCT 2023May 24, 2023 -
insightsASGCT 26th Annual Meeting starts in a few days. This year, it will be held in Los Angeles from May 16 to 20, and Viralgen will be present at booth 123.Read More about Viralgen at the ASGCT 26th Annual MeetingApril 14, 2023 -
insightsRare Disease Day is the globally coordinated movement on rare diseases, working towards equity in social opportunity, healthcare, and access to diagnosis and therapies for people living with a rare...Read More about Rare Disease Day 2023February 2, 2023
-
insightsVisit us at Phacilitate Advanced Therapies Week in Miami, January 17 – 20, 2023, Booth 425. Hear about our recent successes, including our commercial inspection and 2,000L GMP scale AAV...
-
insights-- Certification expands Viralgen's capacity threefold and positions the company as a world-leading CDMO -- -
insightsViralgen is happy to kick off the new year at JPM 2023! Come and join us at a special reception we are hosting at JP Morgan Tuesday evening, January 10.Read More about Join us at JPM 2023January 5, 2023
PREV
NEXT